Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpCancer
• journal#1
Ning Wang, Kerrie Mengersen, Shilu Tong, Michael Kimlin, Maigeng Zhou, Wenbiao Hu
BACKGROUND: China's lung cancer (LC) burden plays a pivotal role in the global cancer epidemic. Comparing LC burden and population attributable fractions (PAFs) of risk factors between China and other countries/regions is essential to inform effective intervention. The Global Burden of Disease (GBD) study provides a unique opportunity for such comparisons. METHODS: We extracted the number of LC deaths, age-standardized death rates (ASDRs), age-standardized disability-adjusted life-year (DALY) rates, and PAFs of risk factors for LC deaths between 1990 and 2017 from GBD 2017...
July 10, 2020: Cancer
#2
Justin G Trogdon, Xuejun Liu, Katherine E Reeder-Hayes, Jason Rotter, Donatus U Ekwueme, Stephanie B Wheeler
BACKGROUND: The objective of the current study was to estimate productivity costs due to metastatic breast cancer (mBC) via productive time lost among survivors and potential life-years lost from premature mortality among 3 age groups: younger (aged 18-44 years), midlife (aged 45-64 years), and older (aged ≥65 years) women. METHODS: The authors estimated the number of work and home productivity days missed due to mBC by age group using data from the 2000 to 2016 National Health Interview Survey...
July 10, 2020: Cancer
#3
Yuki Saito, Ryuichi Hayashi, Yoshiyuki Iida, Takatsugu Mizumachi, Takashi Fujii, Fumihiko Matsumoto, Takeshi Beppu, Masafumi Yoshida, Hirotaka Shinomiya, Ryosuke Kamiyama, Mutsukazu Kitano, Kazuhiko Yokoshima, Yasushi Fujimoto, Takanori Hama, Taku Yamashita, Kenji Okami, Kouki Miura, Takuo Fujisawa, Daisuke Sano, Hisayuki Kato, Shujiro Minami, Masashi Sugasawa, Muneyuki Masuda, Ichiro Ota, Shigemichi Iwae, Ryo Kawata, Nobuya Monden, Takayuki Imai, Takahiro Asakage, Masafumi Okada, Takanori Yoshikawa, Kensuke Tanioka, Megumi Kitayama, Mariko Doi, Satoshi Fujii, Masato Fujii, Nobuhiko Oridate, Munenaga Nakamizo, Seiichi Yoshimoto, Akihiro Homma, Ken-Ichi Nibu, Katsunari Yane
BACKGROUND: Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date. METHODS: The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality...
July 10, 2020: Cancer
#4
Raya Saab, Anas Obeid, Fatiha Gachi, Houda Boudiaf, Lilit Sargsyan, Khulood Al-Saad, Tamar Javakhadze, Azim Mehrvar, Sawsan Sati Abbas, Yasir Saadoon Abed Al-Agele, Salma Al-Haddad, Mouroge Hashim Al Ani, Suleiman Al-Sweedan, Amani Al Kofide, Wasil Jastaniah, Nisreen Khalifa, Elie Bechara, Malek Baassiri, Peter Noun, Jamila El-Houdzi, Mohammed Khattab, Krishna Sagar Sharma, Yasser Wali, Naureen Mushtaq, Aliya Batool, Mahwish Faizan, Muhammad Rafie Raza, Mohammad Najajreh, Mohammed Awad Mohammed Abdallah, Ghada Sousan, Khaled M Ghanem, Ulker Kocak, Tezer Kutluk, Hacı Ahmet Demir, Hamoud Hodeish, Samar Muwakkit, Asim Belgaumi, Abdul-Hakim Al-Rawas, Sima Jeha
BACKGROUND: Childhood cancer is a highly curable disease when timely diagnosis and appropriate therapy are provided. A negative impact of the coronavirus disease 2019 (COVID-19) pandemic on access to care for children with cancer is likely but has not been evaluated. METHODS: A 34-item survey focusing on barriers to pediatric oncology management during the COVID-19 pandemic was distributed to heads of pediatric oncology units within the Pediatric Oncology East and Mediterranean (POEM) collaborative group, from the Middle East, North Africa, and West Asia...
July 10, 2020: Cancer
#5
EDITORIAL
Fadlo R Khuri
No abstract text is available yet for this article.
July 10, 2020: Cancer
#6
LETTER
Paul J Riviere, Brent S Rose
No abstract text is available yet for this article.
July 9, 2020: Cancer
#7
LETTER
Dara J Lundon, Zachary Dovey, Ashutosh K Tewari
No abstract text is available yet for this article.
July 9, 2020: Cancer
#8
Myung Sun Kim, Vinay Prasad
The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab. This approval was based on 2 phase 3 trials: ELEVATE-TN and ASCEND. There are several concerns with the design of these trials, including suboptimal treatment of patients in the control arm, expansion of the trial population, and lack of data regarding efficacy or tolerability compared with ibrutinib, a first-in-class drug...
July 9, 2020: Cancer
#9
LETTER
Connor G Hoge, Jonathan Sussman, Abhinav Sidana
No abstract text is available yet for this article.
July 9, 2020: Cancer
#10
Jung Julie Kang, Richard J Wong, Eric J Sherman, Alisa Rybkin, Sean M McBride, Nadeem Riaz, C Jillian Tsai, Yao Yu, Linda Chen, Kaveh Zakeri, Daphna Y Gelblum, Erin F Gillespie, Marc A Cohen, Jennifer R Cracchiolo, Ian Ganly, Snehal Patel, Bhuvanesh Singh, Jay O Boyle, Benjamin R Roman, Luc G Morris, Ashok R Shaha, Lara A Dunn, Alan L Ho, James V Fetten, Jatin P Shah, David G Pfister, Nancy Y Lee
Because of the national emergency triggered by the coronavirus disease 2019 (COVID-19) pandemic, government-mandated public health directives have drastically changed not only social norms but also the practice of oncologic medicine. Timely head and neck cancer (HNC) treatment must be prioritized, even during emergencies. Because severe acute respiratory syndrome coronavirus 2 predominantly resides in the sinonasal/oral/oropharyngeal tracts, nonessential mucosal procedures are restricted, and HNCs are being triaged toward nonsurgical treatments when cures are comparable...
July 8, 2020: Cancer
#11
Guillaume Ploussard, Christophe Almeras, Jean-Baptiste Beauval, Jean-Romain Gautier, Valérie Garnault, Natacha Frémont, Stéphanie Dallemagne, Guillaume Loison, Ambroise Salin, Christophe Tollon
BACKGROUND: An enhanced recovery after surgery (ERAS) pathway has shown benefit in oncologic surgery. However, literature is scarce regarding the impact of this pathway, alone or combined with prehabilitation (PreHab) programs, on outcomes after robot-assisted radical prostatectomy (RARP). METHODS: Included in this study were 507 consecutive patients undergoing RARP from 2014 to 2019. The primary endpoint was duration of hospital stay. Secondary outcomes included intraoperative blood loss, operative duration, readmission rate, and overall costs...
July 8, 2020: Cancer
#12
Amar J Srivastava, Jessika A Contreras, Melanie Davis, Stephanie T Markovina, Julie K Schwarz, Perry W Grigsby
BACKGROUND: Among patients with cervical cancer, little is known about the significance of persistent human papillomavirus (HPV) expression after chemoradiation (CRT). This study evaluated associations between early posttreatment HPV clearance and patient outcomes with an added focus on the value of posttherapy positron emission tomography (PET) imaging. METHODS: Included patients underwent pretreatment testing indicating a high-risk HPV infection and posttreatment testing with a messenger RNA (mRNA)-based genital swab after CRT...
July 8, 2020: Cancer
#13
Katleen Van der Gucht, Soumaya Ahmadoun, Michelle Melis, Ellen de Cloe, Charlotte Sleurs, Ahmed Radwan, Jeroen Blommaert, Keisuke Takano, Mathieu Vandenbulcke, Hans Wildiers, Patrick Neven, Peter Kuppens, Filip Raes, Ann Smeets, Stefan Sunaert, Sabine Deprez
BACKGROUND: Many breast cancer survivors suffer from cognitive complaints after cancer treatment, affecting their quality of life. The objective of this pilot study was to investigate the effect of a blended-care mindfulness-based intervention (MBI) on chemotherapy-related cognitive impairment and functional brain changes. Furthermore, correlations between changes in cognitive functioning and self-reported behavioral factors were investigated. METHODS: Breast cancer survivors (n = 33) who reported cognitive impairment were randomly allocated to a mindfulness condition (n = 18) or a waitlist control condition (n = 15)...
July 8, 2020: Cancer
#14
EDITORIAL
William Blair Townsend, William M Worrilow, Stephen B Riggs
No abstract text is available yet for this article.
July 8, 2020: Cancer
#15
Henrieke W Schutte, Guido B van den Broek, Stefan C A Steens, Rosella P M G Hermens, Jimmie Honings, Henri A M Marres, Matthias A W Merkx, Willem L J Weijs, Anne I J Arens, Adriana C H van Engen-van Grunsven, Carla M L van Herpen, Johannes H A M Kaanders, Frank J A van den Hoogen, Robert P Takes
BACKGROUND: Timely and efficient diagnostic workup of patients with head and neck cancer (HNC) is challenging. This observational study describes the implementation of an optimized multidisciplinary oncological diagnostic workup for patients with HNC and its impact on diagnostic and treatment intervals, survival, costs, and patient satisfaction. METHODS: All patients with newly diagnosed HNC who underwent staging and treatment at the Radboud University Medical Center were included...
July 7, 2020: Cancer
#16
EDITORIAL
Hala T Borno, Tracy K Lin, Rajaie S Batniji
No abstract text is available yet for this article.
July 6, 2020: Cancer
#17
Uriel Kim, Siran Koroukian, Abby Statler, Johnie Rose
BACKGROUND: Several states have opted to expand Medicaid under the Patient Protection and Affordable Care Act (ACA), which offers insurance coverage to low-income individuals up to 138% of the federal poverty level. This expansion of Medicaid to a medically vulnerable population potentially can reduce cancer outcome disparities, especially among patients with screening-amenable cancers. The objective of the current study was to estimate the effect of Medicaid expansion on the percentage of adults from low-income communities with screening-amenable cancers who present with metastatic disease...
July 6, 2020: Cancer
#18
LETTER
Rick L M Haas, Annalisa Trama, Silvia Stacchiotti
No abstract text is available yet for this article.
July 3, 2020: Cancer
#19
LETTER
Andrej Ozaniak, Zuzana Strizova, Pavel Hladik, Robert Lischke
No abstract text is available yet for this article.
July 3, 2020: Cancer
#20
LETTER
Connor J Kinslow, Tony J C Wang
No abstract text is available yet for this article.
July 3, 2020: Cancer
Fetching more papers... 
